Cross-reactive immunogenicity against Beta and Delta variants
NVSI-06-09 is designed as a potential broad-spectrum COVID-19 vaccine. Besides the Omicron variants, the cross-reactive immunogenicity of NVSI-06-09 booster vaccination was also tested against other immune-evasive variants including Beta and Delta, using BBIBP-CorV as a comparison. A subset of serum samples with sequential numbers collected from 99 participants in NVSI-06-09 group and 100 participants in BBIBP-CorV group were used to evaluate the cross-neutralization against Beta and Delta variants.The results showed that nAb GMTs against Beta and Delta variants induced by NVSI-06-09 booster were 3075.59 (95% CI, 2393.00–3952.89) and 2831.50 (2200.42–3643.58), respectively, which were 6.60-fold and 7.17-fold higher than those boosted by BBIBP-CorV with the GMT values of 465.69 (95% CI, 376.75–575.63) and 395.05 (316.82–492.58) (Fig. The cross-neutralizing antibody titers against Beta and Delta variants induced by the booster vaccination of NVSI-06-09, compared with those boosted with BBIBP-CorV. On 14 days after booster vaccination, a subset of 99 serum samples in NVSI-06-09 booster group and 100 samples in BBIBP-CorV booter group with sequential numbers were tested by using live-virus microneutralization assay. Data are presented as GMTs and 95% CIs. ****: 